FR3147948A1 - Soothing after injection, high tolerance without any contraindications - Google Patents
Soothing after injection, high tolerance without any contraindications Download PDFInfo
- Publication number
- FR3147948A1 FR3147948A1 FR2303957A FR2303957A FR3147948A1 FR 3147948 A1 FR3147948 A1 FR 3147948A1 FR 2303957 A FR2303957 A FR 2303957A FR 2303957 A FR2303957 A FR 2303957A FR 3147948 A1 FR3147948 A1 FR 3147948A1
- Authority
- FR
- France
- Prior art keywords
- skin
- composition according
- soothing
- allantoin
- glycerin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 240000004385 Centaurea cyanus Species 0.000 claims abstract description 17
- 235000005940 Centaurea cyanus Nutrition 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 12
- 229960000458 allantoin Drugs 0.000 claims abstract description 12
- 235000011187 glycerol Nutrition 0.000 claims abstract description 10
- 239000002304 perfume Substances 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 239000005871 repellent Substances 0.000 claims abstract description 6
- 230000002940 repellent Effects 0.000 claims abstract description 6
- 150000003869 acetamides Chemical class 0.000 claims abstract description 5
- 150000001733 carboxylic acid esters Chemical class 0.000 claims abstract description 5
- VZRKEAFHFMSHCD-UHFFFAOYSA-N Ethyl 3-(N-butylacetamido)propionate Chemical compound CCCCN(C(C)=O)CCC(=O)OCC VZRKEAFHFMSHCD-UHFFFAOYSA-N 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 6
- 230000002009 allergenic effect Effects 0.000 claims 1
- 231100000507 endocrine disrupting Toxicity 0.000 claims 1
- 230000036555 skin type Effects 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 16
- 241000255925 Diptera Species 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 7
- 230000007803 itching Effects 0.000 description 6
- VWTINHYPRWEBQY-UHFFFAOYSA-N denatonium Chemical compound [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 description 5
- 206010003399 Arthropod bite Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 108010089414 Anaphylatoxins Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000037307 sensitive skin Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 208000003014 Bites and Stings Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010065259 Dermo-hypodermitis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 229940023184 after bite Drugs 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 239000000598 endocrine disruptor Substances 0.000 description 2
- 231100000049 endocrine disruptor Toxicity 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VSMOENVRRABVKN-UHFFFAOYSA-N oct-1-en-3-ol Chemical compound CCCCCC(O)C=C VSMOENVRRABVKN-UHFFFAOYSA-N 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- -1 IL-1α Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 150000007945 N-acyl ureas Chemical class 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000011312 Vector Borne disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229960001610 denatonium benzoate Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000036618 natural shedding Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P17/00—Pest repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Cosmetics (AREA)
Abstract
L’invention concerne une composition apaisante après piqûre haute tolérance pour tout type de peau et sans aucune contre-indication comprenant un répulsif choisi dans la famille des esters carboxyliques et des acétamides et de l’Eau de Bleuet et de l’allantoine et de la glycérine et un parfum dissous dans un solvant hydroalcoolique. The invention relates to a soothing composition after a bite, high tolerance for all skin types and without any contraindications, comprising a repellent chosen from the family of carboxylic esters and acetamides and Cornflower Water and allantoin and glycerin and a perfume dissolved in a hydroalcoholic solvent.
Description
Les moustiques représentent une menace pour la santé humaine car ils transmettent des parasites, des nématodes et des virus. C'est pourquoi différentes méthodes visent à contrôler les populations de moustiques et à empêcher leur contact avec les Hommes, les deux principales étant l’utilisation de répulsifs qui éloignent les moustiques et/ou l’utilisation d’insecticides qui les tuent.Mosquitoes pose a threat to human health because they transmit parasites, nematodes and viruses. For this reason, different methods are used to control mosquito populations and prevent their contact with humans, the two main ones being the use of repellents that keep mosquitoes away and/or the use of insecticides that kill them.
Malgré toutes les techniques de prévention mises en œuvre, le moustique parvient toujours à piquer les êtres humains. C’est une question de survie de leur espèces puisque ce sont les femelles qui piquent pour nourrir leur œufs. Ces insectes sont par ailleurs attirés par des molécules produites par le corps humain ou par des bactéries qui dégradent des composants de la sueur. Par exemple, l'acide lactique et le oct-1-én-3-ol sont deux molécules qui attirent les moustiques.Despite all the prevention techniques implemented, mosquitoes still manage to bite humans. It is a question of survival of their species since it is the females who bite to feed their eggs. These insects are also attracted by molecules produced by the human body or by bacteria that degrade components of sweat. For example, lactic acid and oct-1-en-3-ol are two molecules that attract mosquitoes.
Au-delà même des maladies vectorielles (le moustique est l’animal qui tue le plus d’êtres humains, 627000 morts en 2020 – source institut Pasteur), les piqures de moustiques peuvent avoir des conséquences plus ou moins graves selon les personnes piquées. Lorsque le moustique femelle pique son hôte, elle injecte depuis son hypopharynx de la salive qui contient des agents vasodilatateurs et anticoagulants que le système immunitaire humain détecte comme étrangers . Il y a libération d’histamine, responsable du prurit immédiatement ressenti, de l’érythème et de la papule (Triade de Lewis) qui est de taille modérée et dure quelques heures, voire plusieurs jours.Beyond vector-borne diseases (mosquitoes are the animals that kill the most humans, with 627,000 deaths in 2020 – source: Pasteur Institute), mosquito bites can have more or less serious consequences depending on the people bitten. When the female mosquito bites its host, it injects saliva from its hypopharynx, which contains vasodilating and anticoagulant agents that the human immune system detects as foreign. Histamine is released, which is responsible for the immediately felt itching, erythema and papule (Lewis Triad) which is moderate in size and lasts a few hours or even several days.
Certaines peaux, sensibles ou atopiques par exemple, souffrant d’une altération de la barrière cutanée kératinocitaire ou d’une augmentation de la densité numérique des mastocytes, présentent une symptomatologie encore plus marquée.Some skin types, such as sensitive or atopic skin, suffering from an alteration of the keratinocyte skin barrier or an increase in the numerical density of mast cells, present even more marked symptoms.
Les piqûres d’insectes sont souvent responsables d’effractions cutanées par grattage. Ces effractions sont à l’origine de dermo-hypodermites parfois sévères.Insect bites are often responsible for skin breaks caused by scratching. These breaks are the cause of sometimes severe dermo-hypodermitis.
Les personnes les plus fragiles, comme les enfants par exemple, peuvent faire très rapidement des réactions allergiques allant jusqu’au syndrome de Skeeter, de même les personnes ayant une peau sensible (60% de la population) ou atopique ont rapidement des conséquences annexes à la piqures de moustique.The most fragile people, such as children for example, can very quickly have allergic reactions leading to Skeeter syndrome, similarly people with sensitive skin (60% of the population) or atopic skin quickly have consequences related to mosquito bites.
La présente invention permet de résoudre les problèmes cités ci-dessus en ce qu‘elle consiste en une composition qui soulage très rapidement les effets de la piqure de moustique , c’est-à-dire le prurit, l’érythème et la papule (Triade de Lewis), désinfecte en évitant les dermo-hypodermites parfois sévères, répare la lésion provoquée par la piqure, hydrate pour reconstituer la peau et prévient l’apparition de cicatrices hypertrophiques.The present invention solves the above-mentioned problems in that it consists of a composition which very quickly relieves the effects of mosquito bites, i.e. pruritus, erythema and papule (Lewis Triad), disinfects while avoiding sometimes severe dermo-hypodermitis, repairs the lesion caused by the bite, moisturizes to reconstitute the skin and prevents the appearance of hypertrophic scars.
La présente invention permet en outre d’éliminer les problèmes de tolérance cutanée qui peuvent apparaitre lors de l’utilisation de ce type d’apaisants qui contiennent tous des huiles essentielles, fortement dosés en terpènes et autres perturbateurs endocriniens. La présente invention est garantie très haute tolérance et ne présente aucune contre-indication pour convenir à toutes les peaux, y compris les plus fragiles.The present invention also makes it possible to eliminate skin tolerance problems that may arise when using this type of soothing products, which all contain essential oils, high doses of terpenes and other endocrine disruptors. The present invention is guaranteed to be very highly tolerant and has no contraindications to suit all skin types, including the most fragile.
Dans un mode de réalisation, la présence d’esters carboxyliques et des acétamides comme le butylacétylaminopropanoate d'éthyle ou butylacétylaminopropionate d'éthyle (CAS n°52304-36-6) permet en outre d’éviter un seconde piqure à côté de la zone déjà agressée et prévient contre des lésions complémentaires, la composition comprend de 3% à 10 %, et de préférence 5 %, de butylacétylaminopropanoate d'éthyle.In one embodiment, the presence of carboxylic esters and acetamides such as ethyl butylacetylaminopropanoate or ethyl butylacetylaminopropionate (CAS No. 52304-36-6) also makes it possible to avoid a second sting next to the area already attacked and prevents additional lesions, the composition comprises from 3% to 10%, and preferably 5%, of ethyl butylacetylaminopropanoate.
L’invention concerne une composition comprenant aussi un répulsif choisi dans la famille des esters carboxyliques et des acétamides et au moins un parfum dissous dans un solvant hydroalcoolique comprenant de la glycérine pour hydrater.The invention relates to a composition also comprising a repellent chosen from the family of carboxylic esters and acetamides and at least one perfume dissolved in a hydroalcoholic solvent comprising glycerin for hydration.
Dans un mode de réalisation, elle comprend en outre de l’eau de bleuet,Centaurea cyanus ,pour apaiser la réaction épidermique.In one embodiment, it further comprises cornflower water, Centaurea cyanus , to soothe the epidermal reaction.
Dans un mode de réalisation, elle comprend en outre de l’allantoine pour réparer les lésions causées par la piqure.In one embodiment, it further comprises allantoin to repair the lesions caused by the sting.
Dans un mode de réalisation, les parfums, faiblement concentrés, sont choisis pour leur haute tolérance cutanée.In one embodiment, the fragrances, which are low in concentration, are chosen for their high skin tolerance.
Dans un autre mode de réalisation, le parfum est choisi pour sa haute tolérance cutanée et sans aucun effet secondaire, allergisant et perturbateurs endocriniens.In another embodiment, the fragrance is chosen for its high skin tolerance and without any side effects, allergens and endocrine disruptors.
On entend par solvant hydroalcoolique un mélange d’éthanol et d’eau comprenant de 10 à 70 % d’éthanol surfin.A hydroalcoholic solvent is a mixture of ethanol and water containing 10 to 70% high-quality ethanol.
Dans un mode de réalisation, le solvant hydroalcoolique comprend de 10 à 35 % d’éthanol surfin.In one embodiment, the hydroalcoholic solvent comprises from 10 to 35% of superfine ethanol.
Le solvant hydroalcoolique comprend en outre de la glycérine pour son pouvoir hydratant, solvant et lubrifiant. On entend par glycérine, le glycérol (CAS n°56-81-5), de préférence d’origine végétale.The hydroalcoholic solvent also includes glycerin for its moisturizing, solvent and lubricating power. Glycerin means glycerol (CAS No. 56-81-5), preferably of plant origin.
Dans un mode de réalisation, la composition comprend moins de 1 % de glycérine, de préférence entre 0,01 et 0,5 % de glycérine, de préférence entre 0,01 et 0,1% de glycérine.In one embodiment, the composition comprises less than 1% glycerin, preferably between 0.01 and 0.5% glycerin, preferably between 0.01 and 0.1% glycerin.
L’eau de Bleuet est issue de la distillation à la vapeur des sommités fleuries des fleurs de bleuet,Centaurea cyanus . Cornflower water is produced by steam distillation of the flowering tops of cornflower flowers, Centaurea cyanus .
L’Eau de Bleuet,Centaurea cyanus, a des propriétés anti-inflammatoires en interférant avec le système du complément, après induction de différents états inflammatoires. L'analyse de la composition de cette fraction aqueuse, qui a la capacité de calmer les inflammations, a révélé que cette propriété est due à la présence de polysaccharides, principalement constituée d'acide galacturonique, d'arabinose, de glucose, de rhamnose, de xylose et de galactose.Cornflower Water, Centaurea cyanus , has anti-inflammatory properties by interfering with the complement system, after induction of different inflammatory states. The analysis of the composition of this aqueous fraction, which has the ability to calm inflammations, revealed that this property is due to the presence of polysaccharides, mainly consisting of galacturonic acid, arabinose, glucose, rhamnose, xylose and galactose.
Cette action s'explique par la capacité de la fraction glucidique de l'hydrolat de bleuet à inhiber l'activité des anaphylatoxines, des composants produits lors de l'activation du système du complément avec des fonctions dans la réponse immunitaire et la défense de l'hôte. Ces fragments sont notamment capables de provoquer le relargage des médiateurs de l'inflammation, telles que l'histamine ou les cytokines pro-inflammatoires (TNF-α, IL-1α, IL-6), par les cellules endothéliales, les phagocytes (macrophages, cellules dendritiques) ou les mastocytes, les premières cellules immunitaires activées par les stimuli. Les anaphylatoxines agissent également indirectement sur la dilatation et la perméabilité des capillaires sanguins.This action is explained by the ability of the carbohydrate fraction of cornflower hydrosol to inhibit the activity of anaphylatoxins, components produced during activation of the complement system with functions in the immune response and host defense. These fragments are particularly capable of causing the release of inflammatory mediators, such as histamine or pro-inflammatory cytokines (TNF-α, IL-1α, IL-6), by endothelial cells, phagocytes (macrophages, dendritic cells) or mast cells, the first immune cells activated by stimuli. Anaphylatoxins also act indirectly on the dilation and permeability of blood capillaries.
Pour résumer, l'inhibition de l'activité des anaphylatoxines par l'eau de bleuet permet une décroissance significative dans la production des molécules pro-inflammatoires. Cette propriété fait du bleuet un soin particulièrement adapté aux épidermes les plus sensibles pour aider à les apaiser. Il aide ainsi à calmer et réduire les plaques rouges (érythèmes), les sensations de chaleur, les démangeaisons et les boursouflures (œdèmes) tout en étant totalement toléré par les peaux les plus sensibles.To summarize, the inhibition of anaphylatoxin activity by cornflower water allows a significant decrease in the production of pro-inflammatory molecules. This property makes cornflower a treatment particularly suited to the most sensitive skin to help soothe it. It thus helps to calm and reduce red patches (erythema), sensations of heat, itching and swelling (edema) while being totally tolerated by the most sensitive skin.
Dans un mode de réalisation, la composition comprend moins de 10 % d’eau de bleuet et de préférence entre 5 et 9 % d’eau de bleuet.In one embodiment, the composition comprises less than 10% cornflower water and preferably between 5 and 9% cornflower water.
L’allantoïne végétale se retrouve dans les racines de la grande consoude et dans les graines de céréales. C’est un uréide oxyglycolique. Son utilisation remonte à l’Egypte et à la Chine anciennes. Sa composition chimique est largement reconnue pour n’avoir aucun effet secondaire sur la peau.Allantoin plant is found in the roots of comfrey and in cereal grains. It is an oxyglycolic ureide. Its use dates back to ancient Egypt and China. Its chemical composition is widely recognized to have no side effects on the skin.
L’allantoïne agit comme un actif contribuant à la stimulation de la prolifération cellulaire et la régénération naturelle de la peau. Elle est particulièrement riche en vitamine A, en vitamine C et en vitamine E. Elle contribue très largement à la cicatrisation des plaies en effaçant le tissu cicatriciel nécrotique et favorise le processus de guérison de la peau.Allantoin acts as an active ingredient that helps stimulate cell proliferation and the natural regeneration of the skin. It is particularly rich in vitamin A, vitamin C and vitamin E. It contributes greatly to wound healing by removing necrotic scar tissue and promotes the skin healing process.
Outre ses propriétés régénérantes, l’allantoine élimine les couches supérieures des cellules mortes et soutient la croissance des tissus sains. Elle possède des propriétés kératolytique connues, elle augmente la teneur en eau des cellules, et encourage ainsi la desquamation, l’excrétion naturelle dans le stratum cornéum, la couche externe de la peau.In addition to its regenerative properties, allantoin removes the upper layers of dead cells and supports the growth of healthy tissue. It has known keratolytic properties, increasing the water content of cells, and thus encouraging desquamation, the natural shedding in the stratum corneum, the outer layer of the skin.
L’allantoïne prévient la sècheresse cutanée et assouplit la peau, elle agit comme un hydratant physique et chimique.Allantoin prevents skin dryness and softens the skin, it acts as a physical and chemical moisturizer.
Dans un mode de réalisation, la composition comprend moins de 5 % d’allantoine et de préférence entre 0,1 et 1% d’allantoine.In one embodiment, the composition comprises less than 5% allantoin and preferably between 0.1 and 1% allantoin.
Elle comprend en outre des répulsifs pour prévenir l’ingestion comme le benzoate de dénatonium, commercialisé sous la marque Bitrex.It also includes repellents to prevent ingestion such as denatonium benzoate, marketed under the brand name Bitrex.
Exemple 1 compositions selon l’invention.
Example 1 compositions according to the invention.
Les pourcentages indiqués étant massiquesThe percentages indicated are by mass.
Composition 1
Composition 2
Composition 3
Exemple 2Example 2
Etude d’efficacité de l’effet apaisant et de tolérance cutanée, tests effectués sous contrôle dermatologique.Study of the effectiveness of the soothing effect and skin tolerance, tests carried out under dermatological control.
L’étude a été réalisée des sujets ayant été piqués par un moustique depuis moins de 24h, les consentements éclairés des volontaires ont été recueillis et les critères d’inclusion ont été les suivants, âge 18-70 ans, âge moyen 36 ans.The study was carried out on subjects who had been bitten by a mosquito less than 24 hours ago, informed consent was obtained from the volunteers and the inclusion criteria were as follows: age 18-70 years, mean age 36 years.
Application de l’Apaisant par le biais d’un Roll On, au bout de quelques minutes les démangeaisons doivent avoir disparues.Application of the Soothing Cream using a Roll On, after a few minutes the itching should have disappeared.
L'étude clinique a été menée conformément à la Déclaration d'Helsinki (1964) et ses mises à jour successives. Les données sont obtenues en utilisant le protocole de l'étude, les procédures internes en vigueur et au plus près du guide des Bonnes Pratiques Cliniques CPMP/ICH/135/95 (R2). L’étude a été entièrement réalisée sous la responsabilité d'Insight Research.The clinical study was conducted in accordance with the Declaration of Helsinki (1964) and its successive updates. The data were obtained using the study protocol, current internal procedures and as closely as possible to the Good Clinical Practice guide CPMP/ICH/135/95 (R2). The study was entirely carried out under the responsibility of Insight Research.
L’étude a permis de conclure qu’au niveau de la tolérance cutanée, aucun des sujets n'a rapporté de signes fonctionnels ou physiques pertinents ni présenté de signes cliniques pertinents à J1. Ainsi, en conclusion le produit « BODYGUARD Apaisant après piqûre » est Très Bien Toléré au niveau Cutané.The study concluded that in terms of skin tolerance, none of the subjects reported any relevant functional or physical signs or presented any relevant clinical signs on D1. Thus, in conclusion, the product "BODYGUARD Soothing after sting" is Very Well Tolerated at the Skin Level.
L’étude a permis de conclure qu’au niveau des démangeaisons « BODYGUARD Apaisant après piqure » a induit une diminution statistiquement significative de 94% de l'intensité des démangeaisons après une seule application. Ainsi, le produit « BODYGUARD Apaisant après piqûre » peut revendiquer le label « efficacité apaisante ».The study concluded that in terms of itching, "BODYGUARD Soothing after bite" induced a statistically significant decrease of 94% in the intensity of itching after a single application. Thus, the product "BODYGUARD Soothing after bite" can claim the label "soothing efficacy".
Aussi l’étude a permis d’obtenir une satisfaction de 100% des clients sur les aspects : efficacité de réduction des démangeaisons, soulagement, texture, confort immédiat sur la peau.The study also allowed us to obtain 100% customer satisfaction on the following aspects: effectiveness in reducing itching, relief, texture, immediate comfort on the skin.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2303957A FR3147948A1 (en) | 2023-04-20 | 2023-04-20 | Soothing after injection, high tolerance without any contraindications |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2303957A FR3147948A1 (en) | 2023-04-20 | 2023-04-20 | Soothing after injection, high tolerance without any contraindications |
| FR2303957 | 2023-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR3147948A1 true FR3147948A1 (en) | 2024-10-25 |
Family
ID=87889078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR2303957A Pending FR3147948A1 (en) | 2023-04-20 | 2023-04-20 | Soothing after injection, high tolerance without any contraindications |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR3147948A1 (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1745772A2 (en) * | 2005-07-20 | 2007-01-24 | Beiersdorf AG | Insect repellents with improved activity |
| CN101711725A (en) * | 2009-11-09 | 2010-05-26 | 纳润（厦门）科技有限公司 | Mosquito-repellent perfume and preparation method thereof |
| CN105878052A (en) * | 2016-05-16 | 2016-08-24 | 薛采芳 | Anti-mosquito repellent suitable for high-temperature and high-humidity environment and preparation method of anti-mosquito repellent |
| CN106420510B (en) * | 2016-12-06 | 2019-04-12 | 广州睿森生物科技有限公司 | A kind of mosquito repellent liquid and preparation method thereof |
| DE10349666B4 (en) * | 2003-10-24 | 2020-02-06 | Beiersdorf Ag | Insect repellent preparation |
| CN113318047A (en) * | 2021-06-10 | 2021-08-31 | 山东省润荷卫生材料有限公司 | Mosquito-repellent wet tissue and production method thereof |
| FR3113452A1 (en) * | 2020-06-22 | 2022-02-25 | Laboratoire Astelia | Mosquito Repellent Scent |
| CN114224812A (en) * | 2022-01-13 | 2022-03-25 | 福建省欧赛加日用品有限公司 | Fragrance, comfortable and non-irritating mosquito repellent toilet water containing DEET and preparation method thereof |
-
2023
- 2023-04-20 FR FR2303957A patent/FR3147948A1/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10349666B4 (en) * | 2003-10-24 | 2020-02-06 | Beiersdorf Ag | Insect repellent preparation |
| EP1745772A2 (en) * | 2005-07-20 | 2007-01-24 | Beiersdorf AG | Insect repellents with improved activity |
| CN101711725A (en) * | 2009-11-09 | 2010-05-26 | 纳润（厦门）科技有限公司 | Mosquito-repellent perfume and preparation method thereof |
| CN105878052A (en) * | 2016-05-16 | 2016-08-24 | 薛采芳 | Anti-mosquito repellent suitable for high-temperature and high-humidity environment and preparation method of anti-mosquito repellent |
| CN106420510B (en) * | 2016-12-06 | 2019-04-12 | 广州睿森生物科技有限公司 | A kind of mosquito repellent liquid and preparation method thereof |
| FR3113452A1 (en) * | 2020-06-22 | 2022-02-25 | Laboratoire Astelia | Mosquito Repellent Scent |
| CN113318047A (en) * | 2021-06-10 | 2021-08-31 | 山东省润荷卫生材料有限公司 | Mosquito-repellent wet tissue and production method thereof |
| CN114224812A (en) * | 2022-01-13 | 2022-03-25 | 福建省欧赛加日用品有限公司 | Fragrance, comfortable and non-irritating mosquito repellent toilet water containing DEET and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| ANONYMOUS: "Qu'est-ce que le bleuet et quels sont ses bienfaits pour votre rituel de soin quotidien ? - Garnier", 11 August 2020 (2020-08-11), XP093092065, Retrieved from the Internet <URL:https://web.archive.org/web/20200811000609/https://www.garnier.fr/conseils/pourquoi-utiliser-le-bleuet-dans-votre-rituel-de-soin> [retrieved on 20231016] * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2878496A1 (en) | Use of a myrtle extract as an anti-biofilm agent against p. acnes | |
| CN108056931A (en) | A kind of acne eliminating cream and preparation method thereof | |
| FR3147948A1 (en) | Soothing after injection, high tolerance without any contraindications | |
| EP0909557B1 (en) | Use of honey as an agent for decreasing micro-organisms adhesion | |
| EP1194136B1 (en) | Non-solid composition for local application comprising glycerol and alchemilla vulgaris extract | |
| EP2692332B1 (en) | Composition for the treatment of callus, corns and psoriasis | |
| FR2700956A1 (en) | Cosmetic and pharmaceutical composition and process for its preparation | |
| DE69727154T2 (en) | LAND AND SEA TURTLE OILS, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION AND USE THEREOF | |
| JP5561365B2 (en) | Long-lasting antipruritic skin preparation | |
| WO2006045963A2 (en) | Composition of cosmetic or pharmacological application for stimulation of synthesis of collagen | |
| US20040185115A1 (en) | Emu oil based methods and compositions for skin ailments | |
| EP0424444B1 (en) | Cosmetic compositions based on chromone-carboxylate | |
| US9364510B2 (en) | Botanical composition and methods of manufacture and use | |
| RU2402345C2 (en) | Alhagi pseudalhagi EXTRACT, BASED PHARMACEUTICAL AND COSMETIC COMPOSITION, METHODS OF BLOOD CHOLESTEROL AND TRIGLYCERIDES REDUCTION, LIPID OXIDATE LEVEL CONTROL, MICROCIRCULATION IMPROVEMENT AND ANTIOXIDANT PROPERTIES, SKIN IMPROVEMENT, STIMULATION OF COLLAGEN FORMATION, WOUND HEALING AND INFLAMMATION REDUCTION | |
| FR3086542A1 (en) | USE OF AN AGAVE EXTRACT TO STRENGTHEN THE BARRIER FUNCTION OF THE SKIN, SCALP AND / OR MUCOSUS AND MODULATE THE CUTANEOUS MICROBIOTE | |
| US20040185088A1 (en) | Emu oil based methods and compositions for elastomeric devices | |
| FR2896692A1 (en) | NEW COSMETOLOGICAL AND DERMATOLOGICAL COMPOSITIONS BASED ON ALGAE EXTRACTS | |
| US6685965B1 (en) | Process for stabilizing levogyre ascorbic acid (laa), a stable aqueous laa composition, a process for preparing a stable topical solution, an emulsion, a vitamin product, and a method for cosmetic, pharmaceutical or nutritional treatment | |
| WO2021148366A1 (en) | Plant-based composition in a form suitable for topical administration and associated production method | |
| FR2773077A1 (en) | Composition for treatment of wounds and ulcers contains glycerol, sucrose, sorbitol or mannitol | |
| BE677435A (en) | ||
| KR20250001879A (en) | Composition for inhibiting advanced glycation end products containing Ilex x wandoensis and Hericium erinaceum extracts | |
| FR2572652A1 (en) | Pharmaceutical composition for antiseptic use | |
| FR3106057A1 (en) | Cosmetic composition comprising extracts of Padina Pavonica to improve healing of the skin | |
| De Rooster et al. | Honey for wound care: myth or science? Part 1: literature overview |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| EXTE | Extension to a french territory |
Extension state: PF |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20241025 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |